Biotech Values

[DewDiligence]

RPRX continue to issue shifty PR’s about the Androxal program:

http://finance.yahoo.com/news/Repros-Receives-Official-FDA-pz-119822964.html?x=0

Joseph S. Podolski, President and CEO of Repros Therapeutics, commented, "We are appreciative of the FDA's efforts and willingness to allow the joint meeting. We understand their position and we look forward to submitting the final clinical study reports for ZA-203 and ZA-204 to the Division of Reproductive and Urologic Products (DRUP) late in February to support a Type B meeting in March or April with the goal of reaching agreement for the Androxal Phase 3 study design."

Scam biotech companies love to issue PR’s touting planned or hoped-for meetings with the FDA. In this instance, the touted meeting is merely a hope, but even if held it’s doubtful the meeting will resolve the chasm between the company and the FDA over the selection of a suitable primary endpoint.